← Eichor
Study identifier: NCT06768463 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Cytoreductive Gastrectomy After Systemic Therapy Versus Systemic Therapy Alone For Limited Metastasis Gastric Cancer

Condition: Metastatic Gastric Cancer · Gastric Cancer · Systemic Therapy  ·  Sponsor: University Medical Center Ho Chi Minh City (UMC)

PhaseNA
Planned participants250
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The results of the current studies to determine the optimal strategy for metastatic gastric cancer remain contrversial worldwide. Hypothesis: Cytoreductive Gastrectomy After Systemic Therapy will improve survival time for metastasis gastric cancer compared to Systemic Therapy alone.

This description comes directly from the study's public registry record.

Talk to the study team

Vo D Long, Prof.  ·  +84918133915  ·  long.vd@umc.edu.vn

Nguyen V Hai, MD  ·  hai.nv@umc.edu.vn

Always discuss trial participation with your own doctor first.

Locations (1)

University Medical CenterHo Chi Minh City, Ho Chi Minh, VietnamRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06768463